𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age

✍ Scribed by A. Ferrant; C. Doyen; A. Delannoy; L. Van den Bossche; P. Martiat; V. Deneys; M. De Bruyère; A. Bosly; J. L. Michaux; G. Sokal

Publisher
Springer
Year
1992
Tongue
English
Weight
526 KB
Volume
64
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute nonlymphocytic leukem
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside
✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

High-dose cytosine arabinoside in the tr
High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimens
✍ Herzig, Roger H. ;Herzig, Geoffrey P. ;Lazarus, Hillard M. ;Wolff, Steven N. ;Ph 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

High-dose cytosine arabinoside (Ara-C) was used in adult patients with refractory acute nonlymphoblastic leukemia, either alone (3 g/m2 every 12 h X 12 doses) or with 3 additional days of anthracycline antibiotics. The systemic toxicities were similar for both groups without an increase in the group